

**LISTING OF CLAIMS:**

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1. (Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula I:



or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

R<sub>1</sub> is selected from the group consisting of -NHC(O)Y, where Y is C<sub>1</sub>-C<sub>22</sub> alkyl, C<sub>2</sub>-C<sub>22</sub> alkenyl, and C<sub>2</sub>-C<sub>22</sub> alkynyl;

R<sub>2</sub> is selected from the group consisting of -OX, where X is ~~C<sub>1</sub>-C<sub>22</sub>~~ C<sub>1</sub>-C<sub>5</sub> alkyl, ~~C<sub>2</sub>-C<sub>22</sub>~~ C<sub>2</sub>-C<sub>5</sub> alkenyl, and C<sub>2</sub>-C<sub>22</sub> C<sub>2</sub>-C<sub>5</sub> alkynyl; and

R<sub>3</sub> is phosphocholine.

2. (Currently Amended): The method of claim 1 wherein Y is ~~and X are~~ independently C<sub>1</sub>-C<sub>14</sub> alkyl, C<sub>2</sub>-C<sub>14</sub> alkenyl, or C<sub>2</sub>-C<sub>14</sub> alkynyl.

3. (Original): The method of claim 1 wherein:


Y is  $-C_{10}H_{21}$ ; and

X is  $-CH_2CH_3$ ,  $-CH_2CH_2CH_3$ ,  $-CH_2CH_2CH_2CH_3$ , or  $-C_{10}H_{21}$ .


4. (Original): The method of claim 1 wherein Y is  $-C_{11}H_{23}$  and X is  $C_1-C_5$  alkyl.

5. (Currently Amended): The method of claim 1 wherein Y is  $-C_9H_{19}$  and X is  $C_6-C_{11}$  alkyl.


6. (Currently Amended): The method of claim 1, wherein the compound is




3-dodecanamido-2-ethoxypropyl-1-phosphocholine,




3-decanamido-2-ethoxypropyl-1-phosphocholine,




3-decanamido-2-decyloxypropyl-1-phosphocholine,



3-dodecanamido-2-octyloxypropyl-1-phosphocholine,




3-dodecanamido-2-dodecyloxypropyl-1-phosphocholine, or



3-dodecanamido-2-butyloxy-1-phosphocholine; or a combination thereof.

7. (Original): The method of claim 1 wherein the host is a mammal.
8. (Original): The method of claim 1 wherein the host is a human.
9. (Withdrawn): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula II:



or a pharmaceutically acceptable salt or prodrugs thereof,

wherein:

M is C<sub>2</sub>-C<sub>4</sub> alkyl;

X<sub>1</sub> is selected from the group consisting of -S-, -O-, -NH-, and -NHC(O)-;

R<sub>21</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> straight chain alkyl, C<sub>2</sub>-C<sub>20</sub> straight chain alkylene containing not more than four double bonds, and aryl;

R<sub>22</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>20</sub> straight chain alkyl, C<sub>3</sub>-C<sub>20</sub> straight chain alkylene containing not more than four double bonds, and aryl; and

R<sub>23</sub>, R<sub>24</sub>, and R<sub>25</sub> are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, and isopropyl.

10. (Withdrawn): The method of claim 9 wherein

M is -CH<sub>2</sub>CH<sub>2</sub>-;

X<sub>1</sub> is -NHC(O)-;

R<sub>21</sub> is selected from the group consisting of a C<sub>1</sub>-C<sub>16</sub> straight chain alkyl and C<sub>2</sub>-C<sub>16</sub> straight chain alkylene containing not more than one double bond;

R<sub>22</sub> is selected from the group consisting of a C<sub>1</sub>-C<sub>16</sub> straight chain alkyl and C<sub>2</sub>-C<sub>16</sub> straight chain alkylene containing not more than one double bond; and

R<sub>23</sub>, R<sub>24</sub>, and R<sub>25</sub> are each independently hydrogen or methyl.

11. (Withdrawn): The method of claim 9 wherein

R<sub>21</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>16</sub> straight chain alkyl and C<sub>2</sub>-C<sub>16</sub> straight chain alkylene containing not more than one double bond; and


R<sub>22</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>5</sub> straight chain alkyl and C<sub>2</sub>-C<sub>5</sub> straight chain alkylene containing not more than one double bond.

12. (Withdrawn): The method of claim 11 wherein R<sub>21</sub> is C<sub>9</sub>-C<sub>12</sub> alkyl and R<sub>22</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl.

13. (Withdrawn): The method of claim 11 wherein R<sub>21</sub> is C<sub>9</sub>-C<sub>12</sub> alkyl and R<sub>22</sub> is C<sub>1</sub>-C<sub>5</sub> alkyl.

14. (Withdrawn): The method of claim 11 wherein R<sub>21</sub> is C<sub>9</sub>-C<sub>12</sub> alkyl and R<sub>22</sub> is C<sub>8</sub>-C<sub>12</sub> alkyl.

15. (Withdrawn): The method of claim 9 wherein the host comprises a mammal.
16. (Withdrawn): The method of claim 9 wherein the host comprises a human.
17. (Withdrawn): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula III:



or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

Y is selected from the group consisting of -S-, -O-, -NH-, -N(CH<sub>3</sub>)-, -NHC(O)-, and -N(CH<sub>3</sub>)C(O)-;

R<sub>1</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>2</sub>-C<sub>18</sub> alkenyl, C<sub>2</sub>-C<sub>18</sub> alkynyl, and aryl;

X is a covalent bond or methylene that is optionally substituted with a hydroxyl, C<sub>1</sub>-C<sub>20</sub> alkyl, -O-(C<sub>1</sub>-C<sub>20</sub> alkyl), -S-(C<sub>1</sub>-C<sub>20</sub> alkyl), -C(O)N(C<sub>1</sub>-C<sub>20</sub> alkyl), C<sub>2</sub>-C<sub>20</sub> alkenyl, -O-(C<sub>2</sub>-C<sub>20</sub> alkenyl), -S-(C<sub>2</sub>-C<sub>20</sub> alkenyl), -C(O)N(C<sub>2</sub>-C<sub>20</sub> alkenyl), C<sub>2</sub>-C<sub>20</sub> alkynyl, -O-(C<sub>2</sub>-C<sub>20</sub> alkynyl), -S-(C<sub>2</sub>-C<sub>20</sub> alkynyl), or -C(O)N(C<sub>2</sub>-C<sub>20</sub> alkynyl);

J is a C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted from one to three times with methyl or ethyl; and

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are independently hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl.

18. (Withdrawn): The method of claim 17 wherein:

Y is -NHC(O)-;

R<sub>1</sub> is C<sub>6</sub>-C<sub>18</sub> alkyl;

X is -C(H)(O-C<sub>1</sub>-C<sub>18</sub> alkyl)- or -C(H)(O-C<sub>1</sub>-C<sub>18</sub> alkenyl)-;

J is -CH<sub>2</sub>CH<sub>2</sub>-; and

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each methyl.


19. (Withdrawn): The method of claim 18 wherein R<sub>1</sub> is -C<sub>11</sub>H<sub>23</sub> and X is -C(H)(O-C<sub>1</sub>-C<sub>5</sub> alkyl)- or -C(H)(O-C<sub>1</sub>-C<sub>5</sub> alkenyl)-

20. (Withdrawn): The method of claim 18 wherein R<sub>1</sub> is -C<sub>9</sub>H<sub>19</sub> and X is -C(H)(OC<sub>2</sub>H<sub>5</sub>)-

21. (Withdrawn): The method of claim 17 wherein R<sub>1</sub> is -C<sub>9</sub>H<sub>19</sub> and X is -C(H)(OC<sub>10</sub>H<sub>21</sub>)-



22. (Withdrawn): The method of claim 17 wherein the host comprises a mammal.
23. (Withdrawn): The method of claim 17 wherein the host comprises a human.
24. (Withdrawn and Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula IV:



or a pharmaceutically acceptable salt or ~~prodrug~~ thereof,

wherein:

R<sub>1</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>18</sub> alkyl, C<sub>2</sub>-C<sub>18</sub> alkenyl, and C<sub>2</sub>-C<sub>18</sub> alkynyl that is optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amino, or aryl;

X is selected from the group consisting of -NHC(O)-, -N(CH<sub>3</sub>)C(O)-, -C(O)NH-, -C(O)N(CH<sub>3</sub>)-, -S-, -S(O)-, -(SO<sub>2</sub>)-, -O-, -NH-, and -N(CH<sub>3</sub>)-;

R<sub>2</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>14</sub> alkyl, C<sub>2</sub>-C<sub>14</sub> alkenyl, and C<sub>2</sub>-C<sub>14</sub> alkynyl that is optionally substituted from 1 to 5 times with -OH, -COOH, oxo, amino, or aryl;

Y is selected from the group consisting of -NHC(O)-, -N(CH<sub>3</sub>)C(O)-, -C(O)NH-, -C(O)N(CH<sub>3</sub>)-, -S-, -S(O)-, -(SO<sub>2</sub>)-, -O-, -NH-, -N(CH<sub>3</sub>)-, and -OC(O)-;

R<sub>6</sub> is selected from the group consisting of C<sub>2</sub>-C<sub>6</sub> alkyl; C<sub>2</sub>-C<sub>6</sub> alkenyl; and C<sub>2</sub>-C<sub>6</sub> alkynyl; and

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are independently methyl or ethyl, or R<sub>3</sub> and R<sub>4</sub> together form an aliphatic or heterocyclic ring having five or six ring atoms and R<sub>5</sub> is methyl or ethyl.

25. (Withdrawn): The method of claim 24 wherein:

R<sub>2</sub> is C<sub>1</sub>-C<sub>14</sub> alkyl, C<sub>2</sub>-C<sub>14</sub> alkenyl, or C<sub>2</sub>-C<sub>14</sub> alkynyl;


R<sub>6</sub> is -CH<sub>2</sub>CH<sub>2</sub>-; and

R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are each independently CH<sub>3</sub>.

26. (Withdrawn): The method of claim 25 wherein R<sub>2</sub> is C<sub>1</sub>-C<sub>5</sub> alkyl or C<sub>2</sub>-C<sub>5</sub> alkenyl.


27. (Withdrawn): The method of claim 25 wherein R<sub>1</sub> is C<sub>8</sub>-C<sub>12</sub> alkyl and R<sub>2</sub> is C<sub>1</sub>-C<sub>12</sub> alkyl

28. (Withdrawn): The method of claim 25 wherein  $R_1$  is  $C_8$ - $C_{12}$  alkyl and  $R_2$  is  $C_1$ - $C_5$  alkyl.
29. (Withdrawn): The method of claim 25 wherein  $R_1$  is  $C_8$ - $C_{12}$  alkyl and  $R_2$  is  $C_8$ - $C_{12}$  alkyl.
30. (Withdrawn): The method of claim 27 wherein  
 $X$  is  $-NHC(O)$ ,  $-N(CH_3)C(O)-$ ,  $-C(O)NH-$ ,  $-C(O)N(CH_3)$ ; and  
 $Y$  is  $-O-$ ,  $-NH-$ , or  $-N(CH_3)-$ .
31. (Withdrawn): The method of claim 24 wherein the host comprises a mammal.
32. (Withdrawn): The method of claim 24 wherein the host comprises a human.
33. (Withdrawn): The method of claim 24 wherein the compound comprises:




3-dodecanamido-2-ethoxypropyl-1-phosphocholine.

34. (Withdrawn): The method of claim 24 wherein the compound comprises:



3-decanamido-2-ethoxypropyl-1-phosphocholine.

35. (Withdrawn and Currently Amended): A method for treating a host infected with RSV comprising administering an anti-RSV effective amount of a compound of Formula AA-1:



(AA-1)

or a pharmaceutically acceptable salt or prodrug thereof,

wherein:

$X^1$  is  $-\text{NHC(O)}-$ ;

$X^2$  is  $-\text{O}-$ ;

$R^1$  is  $-\text{C}_1\text{-C}_{22}$  alkyl;

$R^2$  is  $-\text{C}_1\text{-C}_{22}$  alkyl;

$R^6$  is  $-\text{CH}_2\text{CH}_2-$ ; and

$R^3$ ,  $R^4$ , and  $R^5$  are methyl.

36. (Withdrawn): The method of claim 35, wherein

$R^1$  is  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-(\text{CH}_2)_5\text{CH}_3$ ,  $-(\text{CH}_2)_6\text{CH}_3$ ,  $-(\text{CH}_2)_7\text{CH}_3$ ,  $-(\text{CH}_2)_8\text{CH}_3$ ,  $-(\text{CH}_2)_9\text{CH}_3$ ,  $-(\text{CH}_2)_{10}\text{CH}_3$ ,  $-(\text{CH}_2)_{11}\text{CH}_3$ ,  $-(\text{CH}_2)_{12}\text{CH}_3$  or  $-(\text{CH}_2)_{13}\text{CH}_3$ ; and  
 $R^2$  is  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-(\text{CH}_2)_5\text{CH}_3$ ,  $-(\text{CH}_2)_6\text{CH}_3$ ,  $-(\text{CH}_2)_7\text{CH}_3$ ,  $-(\text{CH}_2)_8\text{CH}_3$ ,  $-(\text{CH}_2)_9\text{CH}_3$ ,  $-(\text{CH}_2)_{10}\text{CH}_3$ ,  $-(\text{CH}_2)_{11}\text{CH}_3$ ,  $-(\text{CH}_2)_{12}\text{CH}_3$  or  $-(\text{CH}_2)_{13}\text{CH}_3$ .

37. (Withdrawn): The method of claim 36, wherein

$R^1$  is  $-(\text{CH}_2)_8\text{CH}_3$ ,  $-(\text{CH}_2)_9\text{CH}_3$ ,  $-(\text{CH}_2)_{10}\text{CH}_3$ ,  $-(\text{CH}_2)_{11}\text{CH}_3$ ;  $-(\text{CH}_2)_{12}\text{CH}_3$ ,  
or  $-(\text{CH}_2)_{13}\text{CH}_3$ ; and  
 $R^2$  is  $\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-(\text{CH}_2)_5\text{CH}_3$ ,  $-(\text{CH}_2)_6\text{CH}_3$ , or  $-(\text{CH}_2)_7\text{CH}_3$ .

38. (Withdrawn): The method of claim 36, wherein

$R^1$  is  $-(CH_2)_5CH_3$ ,  $-(CH_2)_6CH_3$ ,  $-(CH_2)_7CH_3$ ,  $-(CH_2)_8CH_3$ ,  $-(CH_2)_9CH_3$ ,  $-(CH_2)_{10}CH_3$ ,  $-(CH_2)_{11}CH_3$ , or  $-(CH_2)_{12}CH_3$ ; and

$R^2$  is  $-(CH_2)_6CH_3$ ,  $-(CH_2)_7CH_3$ ,  $-(CH_2)_8CH_3$ ,  $-(CH_2)_9CH_3$ ,  $-(CH_2)_{10}CH_3$ ,  $-(CH_2)_{11}CH_3$ ,  $-(CH_2)_{12}CH_3$ , or  $-(CH_2)_{13}CH_3$ .

39. (Withdrawn): The method of claim 1, wherein the administering is orally, intravenously, parentally, intradermally, subcutaneously, topically, or by inhalation.